Céline Hélène Rouquayrol
Céline Hélène Rouquayrol has worked on the following 11 EPO patent applications which have been published in the last five years:
EP12714163
FORMULATIONS COMPRISING 2 -AMINO- 2- [2- (4 - OCTYLPHENYL) ETHYL]PROPANE -1, 3 - DIOL
- IPC classification:
- A61K 9/16, A61K 31/137, A61P 37/06
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ PATENT GRANTED
EP12729907
WASH SOLUTION AND METHOD FOR AFFINITY CHROMATOGRAPHY
- IPC classification:
- C07K 1/22
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ GRANT OF PATENT INTENDED
EP12756466
COMBINATIONS COMPRISING A S1P RECEPTOR MODULATOR
- IPC classification:
- A61K 31/135, A61K 31/137, A61K 31/343, A61K 31/4525, A61K 45/06, A61P 25/24
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION DEEMED TO BE WITHDRAWN
EP12720757
METHOD OF TREATING VISION DISORDERS
- IPC classification:
- A61P 27/02, C07K 16/22
- Applicant:
- Novartis AG
- Agent:
- Multiple attorneys, Novartis Pharma AG
- Status:
- █ APPLICATION DEEMED TO BE WITHDRAWN
EP14163450
Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
- IPC classification:
- A61K 9/20, A61K 9/48, A61K 31/137, A61P 25/00
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION WITHDRAWN
EP13186359
S1P receptor modulators for treating multiple sclerosis
- IPC classification:
- A61K 31/137, A61K 31/397, A61P 37/06
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION DEEMED TO BE WITHDRAWN
EP13177175
Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
- IPC classification:
- A61K 9/00, A61K 9/20, A61K 9/70, A61K 31/137
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION DEEMED TO BE WITHDRAWN
EP14167553
Combinations comprising MGLUR modulators for the treatment of parkinson's disease
- IPC classification:
- A61K 31/404, A61K 31/4427, A61K 31/4545, A61K 31/465, A61K 31/4709, A61K 31/4725, A61K 45/06, A61P 25/16
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION WITHDRAWN
EP14178519
Compound formulations of 2-amino-1,3-propanediol compounds
- IPC classification:
- A61K 9/00, A61K 31/133, A61K 47/10, A61P 37/00, A61P 37/06
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION WITHDRAWN
EP13701276
SYRINGE
- IPC classification:
- A61K 9/00, A61M 5/28, A61M 5/31, A61M 5/315
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ EXAMINATION IN PROGRESS
EP13753858
USE OF A VEGF ANTAGONIST IN TREATING OCULAR VASCULAR PROLIFERATIVE DISEASES
- IPC classification:
- A61K 38/17, A61K 47/48, A61P 27/02
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ EXAMINATION IN PROGRESS